Tonix Pharmaceuticals (NASDAQ:TNXP) Stock Price Down 13.8% – Time to Sell?

Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP)’s stock price was down 13.8% during mid-day trading on Tuesday . The company traded as low as $0.15 and last traded at $0.17. Approximately 73,990,631 shares were traded during mid-day trading, a decline of 35% from the average daily volume of 113,742,805 shares. The stock had previously closed at $0.19.

Analysts Set New Price Targets

Separately, StockNews.com assumed coverage on shares of Tonix Pharmaceuticals in a report on Sunday. They issued a “hold” rating for the company.

Tonix Pharmaceuticals Stock Performance

The company has a market capitalization of $28.41 million, a P/E ratio of 0.00 and a beta of 2.07. The firm has a 50 day moving average price of $0.30 and a two-hundred day moving average price of $0.27. The company has a debt-to-equity ratio of 0.07, a quick ratio of 2.81 and a current ratio of 3.33.

Tonix Pharmaceuticals (NASDAQ:TNXP) last announced its earnings results on Tuesday, November 12th. The company reported ($0.23) EPS for the quarter, topping the consensus estimate of ($2.03) by $1.80. The business had revenue of $2.82 million for the quarter, compared to the consensus estimate of $2.63 million. Tonix Pharmaceuticals had a negative return on equity of 163.95% and a negative net margin of 1,197.86%. On average, research analysts expect that Tonix Pharmaceuticals Holding Corp. will post -17.63 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Tonix Pharmaceuticals stock. PFG Investments LLC acquired a new position in shares of Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor acquired 218,003 shares of the company’s stock, valued at approximately $72,000. PFG Investments LLC owned approximately 0.12% of Tonix Pharmaceuticals as of its most recent filing with the Securities and Exchange Commission. Institutional investors and hedge funds own 82.26% of the company’s stock.

About Tonix Pharmaceuticals

Tonix Pharmaceuticals Holding Corp., a biopharmaceutical company, focuses on developing, discovering, commercializing, and licensing therapeutics to treat and prevent human disease and alleviate suffering. It markets Zembrace SymTouch and Tosymra for the treatment of acute migraine with or without aura in adults.